Perceptive Advisors LLC
- SEC CIK
- 0001224962
- Latest filing
- Aug 14, 2026
Holdings in Q3 2022
Holdings as of Sep 30, 2022, filed Nov 14, 2022. Long positions only; changes compare share counts with Q2 2022.
- Positions
- 115
- +6 vs. Q2 2022
- Portfolio value
- $3.44B
- +$257.8M (+8.1%) vs. Q2 2022
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| ALDXAldeyra Therapeutics, Inc. | COM | 11,350,085 | $60.6M | 1.8% | +1,446,206+14.6% | Added | History |
| XENEXenon Pharmaceuticals Inc. | COM | 2,122,535 | $76.6M | 2.2% | 00.0% | Unchanged | History |
| RXDXPrometheus Biosciences, Inc. | COM | 1,468,512 | $86.7M | 2.5% | −213,730−12.7% | Reduced | History |
| RLMDRelmada Therapeutics, Inc. | COM | 2,383,478 | $88.2M | 2.6% | +2,262,128+1,864.1% | Added | History |
| IOVAIovance Biotherapeutics, Inc. | COM | 10,248,624 | $98.2M | 2.9% | −1,577,675−13.3% | Reduced | History |
| SWTXSpringWorks Therapeutics, Inc. | COM | 3,470,563 | $99.0M | 2.9% | −396,883−10.3% | Reduced | History |
| CRNXCrinetics Pharmaceuticals, Inc. | COM | 5,321,032 | $104.5M | 3.0% | 00.0% | Unchanged | History |
| Bellus Health Inc New07987C204 | COM NEW | 10,247,073 | $108.2M | 3.1% | +4,712,904+85.2% | Added | – |
| CINCCinCor Pharma, Inc. | COM | 3,306,649 | $108.5M | 3.2% | +987,532+42.6% | Added | History |
| LIANYLianBio | SPONSORED ADS | 57,558,451 | $115.1M | 3.3% | +998,240+1.8% | Added | History |
| AMLXAmylyx Pharmaceuticals, Inc. | COM | 5,472,033 | $154.0M | 4.5% | +1,931,625+54.6% | Added | History |
| GBTGlobal Blood Therapeutics, Inc. | COM | 2,322,247 | $158.1M | 4.6% | −692,807−23.0% | Reduced | History |
| CERECerevel Therapeutics Holdings, Inc. | COM | 6,511,727 | $184.0M | 5.3% | +1,425,000+28.0% | Added | History |
| MRTXMirati Therapeutics, Inc. | COM | 2,784,796 | $194.5M | 5.7% | −82,067−2.9% | Reduced | History |
| FOLDAmicus Therapeutics, Inc. | COM | 27,372,917 | $285.8M | 8.3% | +477,385+1.8% | Added | History |
Options (1)
Puts and calls in the same filing. Amounts are the market value of the underlying shares, which is what 13F reports.
| Security | Class | Puts | Calls |
|---|---|---|---|
| TCDATricida, Inc. | COM | $5.24M | – |
Sold out since Q2 2022 (9)
Positions held at the end of Q2 2022 that are gone from this filing.
| Security | Class | Shares in Q2 2022 | Value in Q2 2022 | % of portfolio in Q2 2022 | History |
|---|---|---|---|---|---|
| LLYEli Lilly & Co | Stock | 100,000 | $32.4M | 1.0% | History |
| ALNYAlnylam Pharmaceuticals, Inc. | COM | 172,991 | $25.2M | 0.8% | History |
| DAWNDay One Biopharmaceuticals, Inc. | Stock | 556,047 | $9.95M | 0.3% | History |
| PRVAPrivia Health Group, Inc. | COM | 273,423 | $7.96M | 0.3% | History |
| NUVBNuvation Bio Inc. | COM CL A | 1,769,701 | $5.73M | 0.2% | History |
| MGNXMacrogenics Inc | COM | 1,227,202 | $3.62M | 0.1% | History |
| FUSNFusion Pharmaceuticals Inc. | COM | 1,052,445 | $2.62M | 0.1% | History |
| RACEFerrari N.V. | COM | 6,200 | $1.14M | <0.1% | History |
| ZYZymergen Inc. | COM | 883,332 | $1.09M | <0.1% | History |